knowledge -WSS

knowledge

author：leisure time 2025-09-06 02:13:57 - browse：1774

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Medtronic CEO on promising devices for diabetes, hypertension

focus

WSS

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Merck, Johnson & Johnson CEOs will testify on high drug prices

Medtronic CEO on promising devices for diabetes, hypertension

Syphilis numbers in the United States reach record heights

Readout Newsletter: What happened with Sarepta's Duchenne data

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Psychedelics group wrestles with new pharma identity

Readout Newsletter: The latest on Novavax, Merck, Bluebird

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

White House pharmacy plagued with problems, investigation finds

Hollywood unions extend contract negotiations for actors

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

CDC recommends rationing of RSV shot due to shortages

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

hotspot

The FDA weighs the risks of candy

Diversifying clinical trials isn't enough to close racial gaps: study

Why you shouldn’t ask, “What country has the best health care?”

Maker of FluMist seeks to allow at

FTC sues over Novant Health acquisition of two N.C. hospitals

Vertex non

hotspot

focus

focus

entertainment